Suppr超能文献

炎症性肠病中的组蛋白去乙酰化酶:新见解

Histone deacetylase in inflammatory bowel disease: novel insights.

作者信息

Li Chunxiao, Gu Shaobo, Zhang Yihong, Zhang Zhenruo, Wang Junzhuo, Gao Ting, Zhong Kangpeng, Shan Keshu, Ye Guoliang, Ke Yini, Chen Yi

机构信息

Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.

Department of Orthopedics, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.

出版信息

Therap Adv Gastroenterol. 2025 Feb 16;18:17562848251318833. doi: 10.1177/17562848251318833. eCollection 2025.

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is characterized by chronic nonspecific intestinal inflammation. Despite considerable efforts, IBD remains a heavy burden on society and human health, with increasing morbidity. Posttranslational modification, especially histone acetylation, is a key process in controlling DNA transcriptional activity. Histone deacetylases (HDACs) play a vital role in the mechanism of IBD pathogenesis through histone and nonhistone protein deacetylation. Herein, we present a summary of different categories of HDACs as well as HDAC inhibitors (HDACis) and analyze the role of HDAC inhibition in alleviating IBD along with its mechanism, as well as clinical potential of HDACis in IBD treatment.

摘要

炎症性肠病(IBD),包括溃疡性结肠炎和克罗恩病,其特征为慢性非特异性肠道炎症。尽管付出了巨大努力,但IBD仍然给社会和人类健康带来沉重负担,发病率不断上升。翻译后修饰,尤其是组蛋白乙酰化,是控制DNA转录活性的关键过程。组蛋白去乙酰化酶(HDACs)通过组蛋白和非组蛋白蛋白质去乙酰化在IBD发病机制中发挥重要作用。在此,我们概述了不同类别的HDACs以及HDAC抑制剂(HDACis),并分析了HDAC抑制在减轻IBD中的作用及其机制,以及HDACis在IBD治疗中的临床潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1172/11831641/661985c18724/10.1177_17562848251318833-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验